Skip to main content
ABUS logo

ABUS · Arbutus Biopharma Corp · Documents

Track ABUS — free
$4.02 -0.05 (-1.23%) At close · Nov 20 Q3 2024 earnings call transcript
Market Cap
$616.24M
Shares
153.29M
Volume · Nov 20 2.99M Avg daily vol (3M) 5.19M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $14.08M up 128.2% 10-K filed Mar 23, 2026 Quarterly report FY2026 Q3 Revenue $299K down 43.5% 10-Q filed Nov 10, 2026 Latest results Net income of $59.1 million; $230 million returned to shareholders 8-K filed Nov 10, 2026 Earnings call Q3 2024 earnings call Held Nov 21, 2024
2026
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA lifts clinical hold on AB-101 program

Arbutus Biopharma Corporation said the FDA lifted its clinical hold on AB-101’s IND application in October 2026, allowing additional clinical development in the United States.

Revenue $299K ▼ 43.5% Net income $59.12M Diluted EPS $0.30
Read from the MD&A section
2 source passages
Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. In October 2026, the United States Food and Drug Administration (FDA) lifted its clinical hold on the Investigational New Drug (IND) application for AB-101, our proprietary oral PD-L1 inhibitor for the treatment of cHBV infection. We are now able to engage in additional clinical development for AB-101 in the United States and are evaluating next steps for the continued development of AB-101. Open the document at this passage
Nov 10
Current report 8-K
Net income of $59.1 million; $230 million returned to shareholders

Arbutus Biopharma reported net income of $59.1 million for the quarter ended September 30, 2026, compared with a net loss of $7.7 million a year earlier. It completed a tender offer in early October 2026, buying 46 million shares at $5.00 per share and returning $230 million to shareholders. Cash, cash equivalents and marketable securities were $337.5 million as of September 30, 2026.

Financial results
4 source passages
For the quarter ended September 30, 2026, the Company's net income was $59.1 million, or net income of $0.30 per basic and diluted common share, as compared to a net loss of $7.7 million, or a net loss of $0.04 per basic and diluted common share, for the quarter ended September 30, 2025. In early October 2026, the Company successfully completed its modified "Dutch Auction" tender offer (the "Offer"), returning $230 million of capital to shareholders. In the Offer, the Company purchased 46 million common shares for cancellation at $5.00 per share, representing approximately 23% of its issued and outstanding common shares as of September 29, 2026. As of September 30, 2026, the Company had cash, cash equivalents and investments in marketable securities of $337.5 million compared to $91.5 million as of December 31, 2025. Open the document at this passage
Oct 22
Current report 8-K Events of Oct 20
FDA Lifts Clinical Hold on AB-101 IND Application

The FDA notified the company that the clinical hold on the IND application for AB-101, its oral PD-L1 inhibitor, has been removed, allowing additional clinical development in the United States. Arbutus is evaluating next steps for AB-101's continued development.

Other events
3 source passages
the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company’s oral PD-L1 inhibitor the clinical hold on the Investigational New Drug (“IND”) application for AB-101 has been removed and that the Company may engage in additional clinical development for AB-101 in the United States Arbutus is evaluating next steps for the continued development of AB-101. Open the document at this passage
Oct 1
Tender offer SC TO-I/A
Tender offer

Arbutus Biopharma Corporation accepted 46,000,000 Shares at US$5.00 per Share, an aggregate US$230 million purchase price representing approximately 23 percent of its outstanding Shares; settlement is expected on or about October 5, 2026.

Sep 30
Tender offer SC TO-I/A
Tender offer

Arbutus expects to purchase 46,000,000 Shares at US$5.00 per Share for an aggregate US$230 million, representing approximately 23% of issued and outstanding Shares; the offer was oversubscribed, so tendered shares will be prorated.

Aug 24
Tender offer SC TO-I
Tender offer AI summary on its way
Aug 21
Tender offer SC TO-C
Tender offer AI summary on its way
Aug 21
Current report 8-K
Other events AI summary on its way
Aug 12
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.01M ▼ 90.6% Net loss $5.14M Diluted EPS -$0.03
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $179.13M ▲ 10054.5% Net income $169.7M Diluted EPS $0.87
Apr 15
Current report 8-K Events of Apr 14
Other events AI summary on its way
Apr 14
Proxy statement DEF 14A Meeting May 26, 2026
Proxy statement AI summary on its way
Mar 23
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $14.08M ▲ 128.2% Net loss $33.5M Diluted EPS -$0.17
Feb 20
Current report 8-K Events of Feb 17
Other events AI summary on its way
Feb 6
Current report 8-K Events of Feb 2
Other events AI summary on its way
Jan 16
Current report 8-K Events of Jan 15
Other events AI summary on its way
2025
Mar 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $6.17M ▼ 66.0% Net loss $69.92M Diluted EPS -$0.38
2024
Showing 1–50 of 197 documents
Key facts CIK 1447028 CUSIP 03879J100 13F (30d) 221 filings 200 filers Visit website Investor relations